Governance Documents

The Board of Directors of GI Dynamics (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follow the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Management Team


Joe Virgilio, President & CEO

Joe brings over 20 years of sales, marketing, and general management experience in the medical device industry. Joe possesses a proven track record of aggressive revenue growth through the development and execution of strategic sales and marketing plans with demonstrated abilities to recruit, train, and motivate a highly effective and specialized cross-functional team. His areas of expertise also include GPO/IDN contracting, organizational development and restructuring, corporate partnerships, and distribution strategies. Additionally, Joe possesses broad experience leading organizational turn-around and integration activities.

Prior to joining GI Dynamics, Joe served as President and General Manager for Amann Girrbach, a global leader in dental CAD/CAM technology. Joe has also held the position of Vice President of Sales, The Americas at Surgical Specialties Corporation, as well as Vice President of Sales and Global Marketing at Aptus Endosystems (acquired by Medtronic). Joe spent the early part of his medical device career at Boston Scientific followed by almost a decade at Medtronic in roles of increasing responsibility.

Joe holds a Bachelor of Arts degree from Colgate University and earned continued education from the University of Pennsylvania, Wharton School of Business and from the University of North Carolina, Chapel Hill, Kenan-Flagler School of Business.


Charles Carter, Chief Financial Officer

Charles brings over 15 years of experience as a finance executive in the medical industry, having worked with a wide variety of life sciences, therapeutics, and medical device companies.

Charles has been serving as a consulting finance executive to a broad array of life sciences companies for Danforth Advisors, LLC since February 2018, and previously from 2012 to 2015. In 2015, Charles joined the Guild for Human Services, Inc., as CFO then returned to Danforth Advisors to resume consulting for life science companies in February 2018.

During his time with Danforth, Charles has served as a senior finance executive for Marina Biotech (NASDAQ: MRNA) and Interleukin Genetics (NASDAQ: ILGN) and continues to serve as the head of finance for numerous privately and venture backed life science companies.

Prior to joining Danforth in 2012, Charles held the position of CFO for Aeris Therapeutics, Inc. and Intelligent Medical Devices, Inc., vice president of finance for Adnexus Therapeutics, Inc., and senior director of financial planning and analysis for Transkaryotic Therapies, Inc. (NASDAQ: TKT).

Charles holds an MBA and MS degree in Molecular Genetics and Cell Biology from the University of Chicago and a BS in Biology from Colgate University.


Stephen Linhares, Vice President of Clinical, Regulatory and Quality

Stephen brings over 30 years of experience in development, regulatory, preclinical and clinical operations, quality and resource management with a focus on medical devices.

Prior to joining GI Dynamics, Stephen held the positions of vice president of regulatory, clinical affairs and quality assurance at Neograft Technologies Inc. and leadership roles at Insulet Corporation, Boston Scientific Corporation Inc., and Phase Forward Inc., as well as vice president roles at PLC Medical Systems.

Stephen brings extensive knowledge of the diabetes disease and medical device space, where he has led 10 clinical trials, multiple CE Mark approvals, and numerous 510(k) clearances. Stephen holds nearly 20 United States and international patents and co-author of two peer-reviewed publications.

Stephen holds a BS in Physics from Bridgewater State College.

Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.


Mark Lerdal

Mark Lerdal brings extensive knowledge and experience as a board director in financial and business development, as well as a proven track record leading multiple mergers and acquisitions.

Mr. Lerdal founded KC Holdings, Inc., a company formed to take KENETECH Corporation private through a management buyout. Mr. Lerdal previously held the position as President and CEO of KENETECH Corporation, one of the world’s largest developer, constructor and operator of wind energy plants.

Mr. Lerdal currently serves as Chairman of the Board for Leaf Clean Energy, Element Markets, LLC and Empower Energies, Inc., and sits on the Board of Directors for Southern Current, Allied Minds, PLC (LSE:ALM), and acts as a consultant to Northleaf Capital Partners. Mr. Lerdal previously served on the Board of Directors to Onsite Energy Corporation, Medley Capital Corporation, Trading Emissions, PLC, TerraForm Power, Inc. and TerraForm Global, Inc.

Mr. Lerdal graduated cum laude from Northwestern University School of Law and earned his Bachelor of Arts in Economics from Stanford University.


Ginger Glaser

Ginger Glaser brings over 25 years of quality and regulatory experience, leading successful medical device organizations, as well as a breadth of knowledge in clinical affairs and engineering. She currently is the Principal for G2 Consulting Services and the Chief Technology Officer for Monteris Medical, where she previously held vice president positions. Ms. Glaser held vice president roles with Boston Scientific and American Medical Systems, prior to its acquisition by Boston Scientific.

Ms. Glaser has a strong understanding of FDA processes and culture. She has led industry-wide task forces and helped numerous organizations obtain global regulatory approvals, including “first in the world” achievements.

Ms. Glaser graduated Cum Laude from Texas A&M University, where she earned her B.S. in Bioengineering and M.S. in Biomedical Engineering.